Genmab A/S Stock

Genmab A/S Liabilities

The The Liabilities of Genmab A/S (GMAB.CO) as of Aug 6, 2026 is 7.03 B USD. In the previous year, The Liabilities was 1.27 B USD — a change of 455.22% (higher).

Liabilities

7.03 BUSD

YoY

455.22%

Last updated:

In 2026, Genmab A/S's total liabilities amounted to 7.03 B USD, a 455.22% difference from the 1.27 B USD total liabilities in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Genmab A/S's Liabilities

Genmab A/S's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Genmab A/S's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Genmab A/S's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Genmab A/S's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Genmab A/S’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Genmab A/S stock

The Liabilities of Genmab A/S is 7.03 B USD in 2026.

The Liabilities of Genmab A/S changed from 1.27 B USD to 7.03 B USD, representing a 455.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Genmab A/S historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Genmab A/S

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Genmab A/S